Karonudib (TH1579) is a novel compound that exerts anti-tumor activities and has recently
entered phase I clinical testing. The aim of this study was to conduct a pre-clinical trial in
patient-derived xenografts to identify the possible biomarkers of response or resistance that
could guide inclusion of patients suffering from metastatic melanoma in phase II clinical
trials. Patient-derived xenografts from 31 melanoma patients with metastatic disease were
treated with karonudib or a vehicle for 18 days. Treatment responses were followed by …

Correction: A patient-derived xenograft pre-clinical trial reveals treatment responses and a
resistance mechanism to karonudib in metastatic melanoma - PMC … Correction: A patient-derived
xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to
karonudib in metastatic melanoma … This corrects the article "A patient-derived xenograft
pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in
metastatic melanoma" in volume 9, 810. …